nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Crucial need for improved pharmacovigilance in pregnancy
|
Mofenson, Lynne M |
|
|
10 |
9 |
p. e560-e562 |
artikel |
2 |
Dolutegravir and pregnancy outcomes including neural tube defects in the USA during 2008–20: a national cohort study
|
Kourtis, Athena P |
|
|
10 |
9 |
p. e588-e596 |
artikel |
3 |
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial
|
Ramgopal, Moti N |
|
|
10 |
9 |
p. e566-e577 |
artikel |
4 |
Global HIV control: is the glass half empty or half full?
|
Nachega, Jean B |
|
|
10 |
9 |
p. e617-e622 |
artikel |
5 |
Highlights of IAS 2023
|
Hayward, Peter |
|
|
10 |
9 |
p. e565 |
artikel |
6 |
Malawi HIV progress: persistence and innovation are needed
|
Hargreaves, James R |
|
|
10 |
9 |
p. e562-e563 |
artikel |
7 |
Metabolic implications and safety of dolutegravir use in pregnancy
|
Dontsova, Valeriya |
|
|
10 |
9 |
p. e606-e616 |
artikel |
8 |
PEPFAR reauthorisation hangs in the balance
|
The Lancet HIV, |
|
|
10 |
9 |
p. e557 |
artikel |
9 |
Rapid access to antiretroviral therapy, receipt of naltrexone, and strengths-based case management versus standard of care for HIV viral load suppression in people with HIV who inject drugs in Russia (LINC-II): an open-label, randomised controlled trial
|
Samet, Jeffrey H |
|
|
10 |
9 |
p. e578-e587 |
artikel |
10 |
Realising long-acting ART as first-line treatment
|
Vijayan, Tara |
|
|
10 |
9 |
p. e558-e559 |
artikel |
11 |
Targeted HIV testing in Spanish emergency departments
|
Castillo, Juan González-Del |
|
|
10 |
9 |
p. e564 |
artikel |
12 |
The urgent need for opioid agonist treatment in Russia
|
Harvey, Leah |
|
|
10 |
9 |
p. e559-e560 |
artikel |
13 |
Trends in HIV prevalence, incidence, and progress towards the UNAIDS 95-95-95 targets in Malawi among individuals aged 15–64 years: population-based HIV impact assessments, 2015−16 and 2020−21
|
Payne, Danielle |
|
|
10 |
9 |
p. e597-e605 |
artikel |